Cargando…

Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data

BACKGROUND: Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, Benjamin J. R., Harrison, Stephanie L., Gupta, Dhiraj, Fazio‐Eynullayeva, Elnara, Underhill, Paula, Lip, Gregory Y. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075382/
https://www.ncbi.nlm.nih.gov/pubmed/34779218
http://dx.doi.org/10.1161/JAHA.121.021970
_version_ 1784701670842695680
author Buckley, Benjamin J. R.
Harrison, Stephanie L.
Gupta, Dhiraj
Fazio‐Eynullayeva, Elnara
Underhill, Paula
Lip, Gregory Y. H.
author_facet Buckley, Benjamin J. R.
Harrison, Stephanie L.
Gupta, Dhiraj
Fazio‐Eynullayeva, Elnara
Underhill, Paula
Lip, Gregory Y. H.
author_sort Buckley, Benjamin J. R.
collection PubMed
description BACKGROUND: Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prevalence of AF in major subtypes of cardiomyopathy and investigate the impact on important clinical outcomes. METHODS AND RESULTS: A retrospective cohort study was conducted using electronic medical records from a global federated health research network, with data primarily from the United States. The TriNetX network was searched on January 17, 2021, including records from 2002 to 2020, which included at least 1 year of follow‐up data. Patients were included based on a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy and concomitant AF. Patients with cardiomyopathy and AF were propensity‐score matched for age, sex, race, and comorbidities with patients who had a cardiomyopathy only. The outcomes were 1‐year mortality, hospitalization, incident heart failure, and incident stroke. Of 634 885 patients with cardiomyopathy, there were 14 675 (2.3%) patients with hypertrophic, 90 117 (7.0%) with restrictive, and 37 685 (5.9%) with dilated cardiomyopathy with concomitant AF. AF was associated with significantly higher odds of all‐cause mortality (odds ratio [95% CI]) for patients with hypertrophic (1.26 [1.13–1.40]) and dilated (1.36 [1.27–1.46]), but not restrictive (0.98 [0.94–1.02]), cardiomyopathy. Odds of hospitalization, incident heart failure, and incident stroke were significantly higher in all cardiomyopathy subtypes with concomitant AF. Among patients with AF, catheter ablation was associated with significantly lower odds of all‐cause mortality at 12 months across all cardiomyopathy subtypes. CONCLUSIONS: Findings of the present study suggest AF may be highly prevalent in patients with cardiomyopathy and associated with worsened prognosis. Subsequent research is needed to determine the usefulness of screening and multisdisciplinary treatment of AF in this population.
format Online
Article
Text
id pubmed-9075382
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90753822022-05-10 Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data Buckley, Benjamin J. R. Harrison, Stephanie L. Gupta, Dhiraj Fazio‐Eynullayeva, Elnara Underhill, Paula Lip, Gregory Y. H. J Am Heart Assoc Original Research BACKGROUND: Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prevalence of AF in major subtypes of cardiomyopathy and investigate the impact on important clinical outcomes. METHODS AND RESULTS: A retrospective cohort study was conducted using electronic medical records from a global federated health research network, with data primarily from the United States. The TriNetX network was searched on January 17, 2021, including records from 2002 to 2020, which included at least 1 year of follow‐up data. Patients were included based on a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy and concomitant AF. Patients with cardiomyopathy and AF were propensity‐score matched for age, sex, race, and comorbidities with patients who had a cardiomyopathy only. The outcomes were 1‐year mortality, hospitalization, incident heart failure, and incident stroke. Of 634 885 patients with cardiomyopathy, there were 14 675 (2.3%) patients with hypertrophic, 90 117 (7.0%) with restrictive, and 37 685 (5.9%) with dilated cardiomyopathy with concomitant AF. AF was associated with significantly higher odds of all‐cause mortality (odds ratio [95% CI]) for patients with hypertrophic (1.26 [1.13–1.40]) and dilated (1.36 [1.27–1.46]), but not restrictive (0.98 [0.94–1.02]), cardiomyopathy. Odds of hospitalization, incident heart failure, and incident stroke were significantly higher in all cardiomyopathy subtypes with concomitant AF. Among patients with AF, catheter ablation was associated with significantly lower odds of all‐cause mortality at 12 months across all cardiomyopathy subtypes. CONCLUSIONS: Findings of the present study suggest AF may be highly prevalent in patients with cardiomyopathy and associated with worsened prognosis. Subsequent research is needed to determine the usefulness of screening and multisdisciplinary treatment of AF in this population. John Wiley and Sons Inc. 2021-11-15 /pmc/articles/PMC9075382/ /pubmed/34779218 http://dx.doi.org/10.1161/JAHA.121.021970 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Buckley, Benjamin J. R.
Harrison, Stephanie L.
Gupta, Dhiraj
Fazio‐Eynullayeva, Elnara
Underhill, Paula
Lip, Gregory Y. H.
Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
title Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
title_full Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
title_fullStr Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
title_full_unstemmed Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
title_short Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real‐World Data
title_sort atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real‐world data
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075382/
https://www.ncbi.nlm.nih.gov/pubmed/34779218
http://dx.doi.org/10.1161/JAHA.121.021970
work_keys_str_mv AT buckleybenjaminjr atrialfibrillationinpatientswithcardiomyopathyprevalenceandclinicaloutcomesfromrealworlddata
AT harrisonstephaniel atrialfibrillationinpatientswithcardiomyopathyprevalenceandclinicaloutcomesfromrealworlddata
AT guptadhiraj atrialfibrillationinpatientswithcardiomyopathyprevalenceandclinicaloutcomesfromrealworlddata
AT fazioeynullayevaelnara atrialfibrillationinpatientswithcardiomyopathyprevalenceandclinicaloutcomesfromrealworlddata
AT underhillpaula atrialfibrillationinpatientswithcardiomyopathyprevalenceandclinicaloutcomesfromrealworlddata
AT lipgregoryyh atrialfibrillationinpatientswithcardiomyopathyprevalenceandclinicaloutcomesfromrealworlddata